Loading clinical trials...
Loading clinical trials...
A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
Conditions
Interventions
PBCAR269A
Fludarabine
+2 more
Locations
5
United States
City of Hope
Duarte, California, United States
University of California San Francisco
San Francisco, California, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Columbia University Irving Medical Center
New York, New York, United States
MD Anderson
Houston, Texas, United States
Start Date
April 30, 2020
Primary Completion Date
October 19, 2022
Completion Date
October 19, 2022
Last Updated
September 21, 2023
NCT07523555
NCT06285318
NCT06669247
NCT07497165
NCT04973605
NCT05862012
Lead Sponsor
Precision BioSciences, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions